#ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep

• Lupus Low Disease Activity State Attainment Provides Significant Protection Aga…

Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21 ⏰19:00 ET ⏰Midnight GMT- I promise to be well-caffeinated to present my many highlights from today! 😄 📺Register via the Zoom link below or watch on Youtube https://t.co/6HIQGR5T8z

• Dr. John Cush on Twitter: "Rheumatologists and Health Professionals: Join …

beautifully chaired by @cappelliMD also elegant talk on 'M-triad' by the always articulate @lovetolearn27, made me think about my pt on the ward right now! #ACR21 @RheumNow @CCalabreseDO @LCalabreseDO @got_rheum @MarieKostine @lexmeara @ReidMDMPH @NilashaGhosh @RheumDr_Nina https://t.co/2iu6zWp8Ge

*️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX) ⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA) →2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P *️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS

Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs: similar: - importance of confirming dx well - cautious adoption steroid-sparing Rx different: - clear benefit hard/early Rx - dx metrics aided by tech #ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP

Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #COVID19 vaccines in people with #lupus @RheumNow https://t.co/pru9dTH4z7

• Update on Safety, Effectiveness of SARS-CoV-2 vaccines in SLE | RheumNow

⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts ➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated! Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q

Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients Rubbert-Roth and colleagues found: - RA patients developed anti-S1 antibodies slower and lower compared to controls - Reduced titers among Abatacept & JAKi users #ACR21 @RheumNow https://t.co/sXW8d53O8m

Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below. https://t.co/sxQuP28APX Or visit our YouTube channel-RheumNow. https://t.co/sohrPTB16S https://t.co/LXWaBFOdHO

• https://bit.ly/2ZU2aKn
• https://bit.ly/3qas9rO

Post-Hoc of ASCORE trial: ➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz ➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below! Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW

Cathepsin K - has some promise in Knee OA - now going to Phase 3 @RheumNow https://t.co/exUFqcCJy1

NORD-STAR Trial: outcomes in tx-naïve, early RA pts after 48w of csDMARDs+GC vs bDMARD (ABAtacept, CerToliZumab, or ToCiluZumab)+MTX ➡️ Superior CDAI remission rates w/ ABA+MTX & CZP+MTX but not TCZ+MTX vs csDMARD+GC ➡️Imaging progression low in all Abst#0825 #ACR21 @RheumNow https://t.co/QaFIF4WNEG

#ACR21 #Abstr0871 📢Argument against HCQ<5mg/kg dose from cardiac perspective in #lupus. A retrospective study N=296 pts, 13% developed CV events.⬇️28% in risk of heart failure, arrhythmia/cardiac death per mg/kg of HCQ in non-smokers @RheumNow #ACRBest https://t.co/6ssd2159R1 https://t.co/tllPWLnFFj

• The Association of Hydroxychloroquine Dosing with Adverse Cardiovascular Events…